Format

Send to

Choose Destination
See comment in PubMed Commons below
Biol Psychiatry. 2015 Oct 15;78(8):572-81. doi: 10.1016/j.biopsych.2014.04.010. Epub 2014 Apr 26.

Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.

Author information

  • 1Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich and Swiss Federal Institute of Technology, Zurich, Switzerland; Department of Neuropsychopharmacology and Brain Imaging, University of Zurich and Swiss Federal Institute of Technology, Zurich, Switzerland. Electronic address: r.kraehenmann@bli.uzh.ch.
  • 2Department of Neuropsychopharmacology and Brain Imaging, University of Zurich and Swiss Federal Institute of Technology, Zurich, Switzerland.
  • 3Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich and Swiss Federal Institute of Technology, Zurich, Switzerland; Department of Neuropsychopharmacology and Brain Imaging, University of Zurich and Swiss Federal Institute of Technology, Zurich, Switzerland; Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich; and Institute for Biomedical Engineering, University of Zurich and Swiss Federal Institute of Technology, Zurich, Switzerland.
  • 4Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich and Swiss Federal Institute of Technology, Zurich, Switzerland.

Abstract

BACKGROUND:

The amygdala is a key structure in serotonergic emotion-processing circuits. In healthy volunteers, acute administration of the serotonin 1A/2A/2C receptor agonist psilocybin reduces neural responses to negative stimuli and induces mood changes toward positive states. However, it is little-known whether psilocybin reduces amygdala reactivity to negative stimuli and whether any change in amygdala reactivity is related to mood change.

METHODS:

This study assessed the effects of acute administration of the hallucinogen psilocybin (.16 mg/kg) versus placebo on amygdala reactivity to negative stimuli in 25 healthy volunteers using blood oxygen level-dependent functional magnetic resonance imaging. Mood changes were assessed using the Positive and Negative Affect Schedule and the state portion of the State-Trait Anxiety Inventory. A double-blind, randomized, cross-over design was used with volunteers counterbalanced to receive psilocybin and placebo in two separate sessions at least 14 days apart.

RESULTS:

Amygdala reactivity to negative and neutral stimuli was lower after psilocybin administration than after placebo administration. The psilocybin-induced attenuation of right amygdala reactivity in response to negative stimuli was related to the psilocybin-induced increase in positive mood state.

CONCLUSIONS:

These results demonstrate that acute treatment with psilocybin decreased amygdala reactivity during emotion processing and that this was associated with an increase of positive mood in healthy volunteers. These findings may be relevant to the normalization of amygdala hyperactivity and negative mood states in patients with major depression.

KEYWORDS:

Amygdala; Depression; Emotion; Psilocybin; Serotonin; fMRI

PMID:
24882567
DOI:
10.1016/j.biopsych.2014.04.010
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center